Resurrection of sildenafil: potential for Huntington's Disease, too?
Jannis AchenbachSimon FaissnerCarsten SaftPublished in: Journal of neurology (2022)
The phosphodiesterase-5 inhibitor sildenafil was postulated to reduce the risk for Alzheimer's Disease. Since preclinical data revealed beneficial effects in Huntington's Disease (HD), we now for the first time investigated effects of sildenafil in HD patients using the database ENROLL-HD. We demonstrate beneficial effects on motoric, functional and cognitive capacities in cross-sectional data. Those effects were not explained by underlying fundamental molecular genetic or demographic data. It remains unsolved, if effects are due to behavioral differences or due to direct dose-dependent neurobiological modulations.
Keyphrases
- electronic health record
- pulmonary hypertension
- pulmonary arterial hypertension
- cross sectional
- end stage renal disease
- big data
- newly diagnosed
- ejection fraction
- chronic kidney disease
- stem cells
- gene expression
- cognitive decline
- data analysis
- mesenchymal stem cells
- bone marrow
- cell therapy
- human health
- atomic force microscopy
- climate change
- copy number